About glofitamab
CD20×CD3 bispecific antibody
Used for
- Treats adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments.
Usual adult dose
Intravenous step-up dosing: 2.5 mg on day 8 of cycle 1, then 10 mg on day 15, then 30 mg every 21 days from cycle 2; treatment lasts up to 12 cycles.
Common side effects
- Cytokine release syndrome
- Low blood cell counts
- Fever and fatigue
- Infections
Important warnings
- Cytokine release syndrome can be severe or life-threatening.
- Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, can occur.
- Serious infections and tumor flare can occur.
- Requires step-up dosing and premedication; treatment begins with obinutuzumab.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for two months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for two months after the last dose.
Interactions
- No major metabolic drug interactions are established; formal interaction studies are limited.
- Other medicines that suppress the immune system may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.